Kangfang Biotechnology (Cayman) Limited completed a new share placement on October 21, 2024. According to the placement agreement dated October 11, 2024, the company issued 31,700,000 new shares under a general authorization. This placement resulted in a 3.66% increase in the issued shares of the company (excluding treasury shares), with an issuance price of HKD 61.28 per share. Prior to the placement, the company had 865,857,176 issued shares, which increased to 897,557,176 shares after the placement. The company confirms that this share issuance has been formally approved by the board of directors and complies with all applicable listing rules, laws, and other regulatory requirements. Director Xia Yu of the company confirmed the above information on the submission date.

Kangfang Biotechnology (Cayman) Limited completed a new share placement on October 21, 2024. According to the placement agreement dated October 11, 2024, the company issued 31,700,000 new shares under a general authorization. This placement resulted in a 3.66% increase in the issued shares of the company (excluding treasury shares), with an issuance price of HKD 61.28 per share. Prior to the placement, the company had 865,857,176 issued shares, which increased to 897,557,176 shares after the placement. The company confirms that this share issuance has been formally approved by the board of directors and complies with all applicable listing rules, laws, and other regulatory requirements. Director Xia Yu of the company confirmed the above information on the submission date.